---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-24-000125"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:33:31.566837+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lifecore reports FY 2024 revenue $128.3M (+24.2%), Adj. EBITDA $20.2M; FY25 rev guidance $126.5-130M

## Summary
- FY 2024 revenue $128.3M (+24.2% YoY); Q4 revenue $37.9M (+21.6% YoY).
- FY 2024 net income $9.3M (incl. $39.5M non-cash gain) vs loss $64.2M; Adj. EBITDA $20.2M.
- Q4 net loss $7.1M vs $37.0M (prior yr had $23.7M debt extinguish loss); Adj. EBITDA $10.4M.
- FY 2025 guidance: rev $126.5-130M, Adj. EBITDA $19-21M, capex $10-14M.
- 5-head isolator filler GMP-ready Sept 2024; headcount reduced in July; SEC filings current.

## SEC filing metadata
- accession: 0001005286-24-000125
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000125/0001005286-24-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528624000125/lndc-20240826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-24-000125
- JSON: https://secwatch.observer/filing/0001005286-24-000125.json
- Plain text: https://secwatch.observer/filing/0001005286-24-000125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.